1. Home
  2. FGEN vs LSTA Comparison

FGEN vs LSTA Comparison

Compare FGEN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • LSTA
  • Stock Information
  • Founded
  • FGEN 1993
  • LSTA 1980
  • Country
  • FGEN United States
  • LSTA United States
  • Employees
  • FGEN N/A
  • LSTA N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • FGEN Health Care
  • LSTA Health Care
  • Exchange
  • FGEN Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • FGEN 34.5M
  • LSTA 31.2M
  • IPO Year
  • FGEN 2014
  • LSTA N/A
  • Fundamental
  • Price
  • FGEN $0.50
  • LSTA $2.61
  • Analyst Decision
  • FGEN
  • LSTA Strong Buy
  • Analyst Count
  • FGEN 0
  • LSTA 1
  • Target Price
  • FGEN N/A
  • LSTA $15.00
  • AVG Volume (30 Days)
  • FGEN 885.8K
  • LSTA 66.3K
  • Earning Date
  • FGEN 02-24-2025
  • LSTA 02-27-2025
  • Dividend Yield
  • FGEN N/A
  • LSTA N/A
  • EPS Growth
  • FGEN N/A
  • LSTA N/A
  • EPS
  • FGEN N/A
  • LSTA N/A
  • Revenue
  • FGEN $180,015,000.00
  • LSTA N/A
  • Revenue This Year
  • FGEN $21.91
  • LSTA N/A
  • Revenue Next Year
  • FGEN N/A
  • LSTA N/A
  • P/E Ratio
  • FGEN N/A
  • LSTA N/A
  • Revenue Growth
  • FGEN 16.15
  • LSTA N/A
  • 52 Week Low
  • FGEN $0.18
  • LSTA $2.19
  • 52 Week High
  • FGEN $2.93
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 49.50
  • LSTA 42.17
  • Support Level
  • FGEN $0.46
  • LSTA $2.45
  • Resistance Level
  • FGEN $0.51
  • LSTA $2.74
  • Average True Range (ATR)
  • FGEN 0.05
  • LSTA 0.32
  • MACD
  • FGEN -0.01
  • LSTA -0.05
  • Stochastic Oscillator
  • FGEN 31.25
  • LSTA 16.48

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: